Redefining 'Plasticity' in Psychedelic Neuroscience Research

Recent Paper Calls for Precision in 'Plasticity' Terminology

A September 2026 analysis published via OpenAlex (W7160992567) challenges the prevailing use of the term 'plasticity' in neuroscience and psychedelic therapy research. The authors argue that the term has become a catch-all explanation for observed brain changes following psychedelic administration, leading to conceptual confusion and overgeneralized claims about therapeutic mechanisms. They propose a more rigorous framework—mediational and recalibrative plasticity (MR-P)—to better align biomarkers with clinically meaningful outcomes.

Mechanistic Distinctions: Plasticity Proper vs. Neuroplasticity

Plasticity, in its original sense ('plasticity proper'), refers to the capacity of a system to be shaped or molded. In neuroscience, however, 'neuroplasticity' often denotes any induced change in brain structure or function, typically measured via biomarkers such as synaptic density, dendritic spine growth, or functional connectivity. The paper highlights that many popular biomarkers index only a subset of brain changes, often those linked to learning or adaptation, and may paradoxically reinforce fixed phenotypes—a process distinct from true plasticity proper.

This distinction is critical for psychedelic research, where increases in certain neuroplasticity markers are frequently cited as evidence of therapeutic potential. The authors caution that not all evoked brain changes equate to clinically beneficial plasticity, and biomarkers alone may not reliably predict mental health outcomes. The MR-P framework aims to clarify which neurobiological changes genuinely mediate or recalibrate mental health–relevant phenotypes, rather than merely reflecting transient or context-dependent brain activity.

Implications for Clinical Trials and Regulatory Review

The call for greater rigor in defining and measuring plasticity has direct implications for the design and interpretation of psychedelic clinical trials. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly scrutinize mechanistic claims and biomarker endpoints in investigational new drug (IND) applications and marketing submissions. Overgeneralized references to 'plasticity' may undermine the evidentiary basis for linking brain changes to clinical benefit, affecting the credibility of trial outcomes and the likelihood of regulatory approval.

• Trial sponsors may need to pre-specify which biomarkers reflect MR-P, rather than relying on broad neuroplasticity measures.
• Funders and institutional review boards (IRBs) could require clearer mechanistic rationales for proposed interventions.
• Communicating nuanced findings to patients and the public will become increasingly important to avoid overpromising based on ambiguous biological signals.

Notably, the MR-P framework also offers a decision criterion for distinguishing between biomarkers that are merely correlative and those that are causally linked to durable mental health improvements—a distinction often overlooked in prior literature.

Risks, Unknowns, and the Limits of Biomarker Interpretation

Relying on undifferentiated plasticity claims carries the risk of misinterpreting or overstating the translational value of preclinical and early-phase trial results. For example, increases in synaptic markers following psilocybin or ketamine administration may not consistently translate to improved patient outcomes, particularly if the underlying brain changes are context-dependent or reversible. The authors emphasize that context, timing, and individual variability all modulate the relationship between observed brain changes and therapeutic effect.

Another failure mode is the potential for 'biomarker drift,' where surrogate endpoints are adopted in lieu of validated clinical outcomes, leading to regulatory setbacks or post-approval disappointments. This risk is heightened in psychedelic research, where enthusiasm for novel mechanisms can outpace the development of robust translational models.

Looking Forward: Toward More Rigorous Mechanistic Science

The proposed MR-P framework invites the field to move beyond catch-all explanations and toward more precise, context-sensitive models of how psychedelics may effect change in the brain and behavior. As psychedelic research matures, integrating MR-P into trial protocols and regulatory submissions could improve the interpretability and reproducibility of findings, ultimately benefiting patient care and policy development. Future research should focus on validating MR-P–aligned biomarkers, clarifying causal pathways, and transparently communicating both the promise and limitations of psychedelic-induced brain changes.

How we research / reviewed by Dr. Alex Finch, PhD (Neuroscience), on 2026-09-02.